Physician profile
John M Mullins
NPI 1063434538
$5,768.13
in general payments reported to CMS, 2019-2025
9 companies · $19.86 in 2025
The $19.86 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.42 · 2020: $12.98 · 2021: $939 · 2022: $153 · 2023: $3,829 · 2024: $716 · 2025: $19.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,406 · Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,406.04 |
| Food and Beverage | $159.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,475.34 | 2023-2024 | |
| Merz North America, INC. | $650.90 | 2021 | |
| Galderma Laboratories, L.P. | $319.37 | 2021-2023 | |
| Allergan, INC. | $170.81 | 2019-2022 | |
| Lilly USA, LLC | $72.53 | 2022-2024 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $30.41 | 2020-2021 | |
| Axsome Therapeutics, INC. | $19.86 | 2025 | Auvelity |
| Antares Pharma, INC. | $15.04 | 2021 | |
| Gilead Sciences, INC. | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.